Prellis Biologics, a company developing the tools to create 3D-printed organs, announced a $14.5 million Series B round led by Celesta Capital.
- Company
- Prellis Biologics prellisbio.com
- Value
- $14.5M
- Source
- techcrunch.com
- In the newsletter
- No. 12, The Tech of Terminator 2 & NASA Probes the Sun
Also in Startup News, Dec 21, 2021
- ForwardX Robotics raises $31M Series CFunding
- Dedrone raises $30.5M Series CFunding
- eLeapPower, announced $21 Million in Series A funding led by a consortium of pension funds and BDC Capital's Cleantech PracticeFunding
- Sustaera Inc raises $10M Series AFunding
- Exponent Energy raises $5M Series AFunding